This is a working overview of regulatory status, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2026-08-01. Anything still debated is marked as such rather than presented as settled.
AOD-9604 drew attention in the 1990s and 2000s as a potential anti-obesity agent. Early work explored both injectable and oral routes, which is unusual for a peptide of this size. Animal studies reported changes in fat metabolism without the growth-promoting or insulin-like effects associated with full-length growth hormone. Subsequent human trials produced mixed or modest results, and the compound did not obtain regulatory approval for weight management in major markets. It remains known mainly through research literature, sports anti-doping listings, and non-approved supplement advertising.
AOD-9604 is prohibited in sport by the World Anti-Doping Agency under the peptide hormone class. Its presence in a sample can be detected through mass spectrometry-based methods, although the exact assay depends on the laboratory. In research settings, material is often supplied as a lyophilized powder for reconstitution. Buyers and researchers should note that products labeled AOD-9604 may vary in purity and actual peptide content. Analytical certificates and independent testing are common ways to verify identity, but no global harmonized standard exists for all commercial lots.
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Fragment analog of human growth hormone |
| Sequence basis | hGH 176–191 region | Modified C-terminal fragment |
| Common synonyms | AOD-9604; AOD9604; hGH fragment | Research and trade names vary |
| Regulatory status | Not approved as a drug | Prohibited in competitive sport |
| Research code | AOD9604 | Used in scientific and patent literature |
Regulatory status varies by country. In the United States, AOD-9604 is not approved as a prescription drug. It is sometimes sold as a research chemical or dietary supplement, though such marketing may fall outside legal frameworks. The World Anti-Doping Agency prohibits its use in sport. Researchers must obtain it through legitimate suppliers and follow institutional rules. Its legal classification continues to evolve as authorities increasingly assess peptide products more broadly.
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.
Research on AOD-9604 also examines how the peptide is measured in biological samples. Analytical methods may include liquid chromatography coupled with mass spectrometry, immunoassays, or both. Detection can be challenging because the peptide is small and may be present at low concentrations. Published methods vary in sensitivity and specificity, so comparative interpretation requires attention to validation details. The presence of related hGH fragments can complicate identification in some matrices.
AOD-9604 has been investigated mainly in the context of body fat and metabolic endpoints. Some early animal and small human studies reported changes in fat mass or lipid markers, but findings were not uniform. Larger, well-controlled trials that would establish efficacy are lacking in the public literature. As a result, claims about weight loss or metabolic benefit remain investigational rather than established. The distinction between a research finding and a proven clinical outcome is central to discussing this peptide.
=== Prosecution === Filomena Teixeira said that police did not investigate members of the family, neighbors and Dias' car, in which witnesses said they saw Mendonça go into. She also said she was sexually harassed by one of the investigators."In the Judiciary Police they were incompetent at first, the case was very badly treated. It was the worst nightmare I could have. I was alone fighting against incompetent people. They even told me that they weren't ready for these kind of things. How is that possible? (...) At the time they didn't do anything. They said [that I couldn't] go to the hills [to look for my son]. They said that they didn't like me." "[I] went everyday to the police to know if they had done something. I look in their files, everything was on paper and then there were tapes. In the beginning they had computers and they didn't know how to work with computers, because the officers there were old and didn't know how to work with computers."
=== Hormonal disorders === A meta-analysis found levels of increased circulating resistin in women with polyendocrine metabolic ovarian syndrome (PMOS, formerly polycystic ovary syndrome). This effect was independent of obesity, showing that adipokines like resistin may contribute to the pathology of PMOS.
In an article published by Los Alamos National Laboratory, researchers state, "Because of the very high strength of pure fentanyl powder, it's hard to dilute precisely, so small inaccuracies in weight can cause huge variation between batches, and it's all too easy for someone to get too much."
== Cause == The general cause of cardiac amyloidosis is the misfolding of a specific protein precursor depending on the amyloidosis type. Protein precursors include immunoglobulin-derived light chains and transthyretin. The misfolding of the protein causes it to have insoluble beta-pleated sheets, creating an amyloid. Amyloid, the aggregation, or clumping, of proteins, is resistant to degradation by the body. Amyloids are mostly fibrils, while also containing a P component, apolipoprotein, collagen, fibronectin, and laminin. The P component, a pentameric protein, stabilizes the fibrils of the amyloid, which reduces their clearance from the body. Deposits of amyloid can occur throughout the body, including the heart, liver, kidneys, spleen, adrenal glands, and bones. Deposits in the extracellular cardiac space can stiffen the heart, resulting in restriction of the ventricles. This restriction in ventricular motion results in a decreased ability for the heart to pump efficiently, leading to the various symptoms associated with cardiac amyloidosis. Impaired protein processing (proteostasis) and reduced endoplasmic reticulum degradation of TTR with advancing age are thought to potentially contribute to the delayed presentation of both wild-type and genetic TTR amyloidosis. Both diseases usually presenting after age 60.
2,5-Dimethoxyamphetamine (2,5-DMA), also known as DMA-4 or as DOH, is a psychoactive drug of the phenethylamine and amphetamine families. It is one of the dimethoxyamphetamine (DMA) series of positional isomers. The drug is notable in being the parent compound of the DOx (4-substituted-2,5-dimethoxyamphetamine) series of psychedelic drugs. It is taken orally.
Sources: en.wikipedia.org
=== seg-seo === seganserin (INN) seglitide (INN) Sehippy seladelpar (INN) selamectin Selarsdi Selax Seldane Selecor Select 1/35 Selectol selegiline (INN) selenomethionine (75 Se) (INN) Selepen selepressin (INN) Selestoject seletracetam (USAN, (INN)) selexipag (INN) selfotel (INN) seliciclib (INN) selodenoson (USAN) Selpak selprazine (INN) Selsun Selsun Blue seltraposin (INN) selumetinib (USAN) selurampanel (INN) selvacovatein (INN) semagacestat (USAN, INN) semaglutide (INN) sematilide (INN) semduramicin (INN) Semicid Semilente semorphone (INN) semotiadil (INN) semparatide (INN) Semprex-D semuloparin (USAN, INN) semustine (INN) Senexon senicapoc (USAN) Sennatural senofilcon A (USAN) Senokot Senolax Sensipar Sensorcaine Senvelgo seocalcitol (INN)
=== Gradient === The use of a solvent gradient is very well developed in column chromatography but is less common in CCC. A solvent gradient is produced by increasing (or decreasing) the polarity of the mobile phase during the separation to achieve optimal resolution across a wider range of polarities. For example, a methanol-water mobile phase gradient may be employed using heptane as the stationary phase. This is not possible with all biphasic solvent systems, due to excessive loss of stationary phase created by disruption the equilibrium conditions within the column. Gradients may either be produced in steps, or continuously.
=== Molecular classification === As with bacterial classification, identification of bacteria is increasingly using molecular methods, and mass spectroscopy. Most bacteria have not been characterised and there are many species that cannot be grown in the laboratory. Diagnostics using DNA-based tools, such as polymerase chain reaction, are increasingly popular due to their specificity and speed, compared to culture-based methods. These methods also allow the detection and identification of "viable but nonculturable" cells that are metabolically active but non-dividing. The main way to characterize and classify these bacteria is to isolate their DNA from environmental samples and mass-sequence them. This approach has identified thousands, if not millions of candidate species. Based on some estimates, more than 43,000 species of bacteria have been described, but attempts to estimate the true number of bacterial diversity have ranged from 107 to 109 total species—and even these diverse estimates may be off by many orders of magnitude.
Octopuses offer many possibilities in biological research; the California two-spot octopus had its genome sequenced, allowing exploration of its molecular adaptations. Having independently evolved mammal-like intelligence, octopuses were compared by the philosopher Peter Godfrey-Smith, who studied the nature of intelligence, to hypothetical intelligent extraterrestrials. Their intelligence and flexible bodies enable them to escape from supposedly secure tanks in public aquariums. Due to their intelligence, many argue that octopuses should be given protections when used for experiments. In the UK from 1993 to 2012, the common octopus (Octopus vulgaris) was the only invertebrate protected under the Animals (Scientific Procedures) Act 1986. In 2012, this legislation was extended to include all cephalopods in accordance with a general EU directive. Some robotics research is exploring biomimicry of octopus features. Octopus arms can move and sense largely autonomously without intervention from the animal's central nervous system. In 2015 a team in Italy built soft-bodied robots able to crawl and swim, requiring only minimal computation. In 2017, a German company made an arm with a soft pneumatically controlled silicone gripper fitted with two rows of suckers. It was able to grasp objects such as a metal tube, a magazine, or a ball, and to fill a glass by pouring water from a bottle.
(chaotropic) When oppositely charged kosmotropic cations and anions are in solution together, they are attracted to each other, rather than to water, and the same can be said for chaotropic cations and anions. Thus, the preferential associations of oppositely charged ions can be ordered as:
Sources: en.wikipedia.org
No. It is a synthetic peptide fragment modeled on part of human growth hormone, not the full hormone. It does not contain the complete sequence or receptor-binding regions of hGH.
It was investigated in clinical trials for obesity, but it did not receive approval for that use in major markets. Results were generally modest or mixed, and it remains an experimental compound.
WADA lists it as a prohibited peptide hormone. Its use can be detected by laboratory methods, and athletes are subject to sanctions if it is found in samples.
It is a synthetic peptide fragment derived from the C-terminal region of human growth hormone, commonly referred to as hGH fragment 176-191. It has been investigated for effects on fat metabolism, but it is not an approved medication in most jurisdictions.